

Akshay Sharma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8751383/publications.pdf>

Version: 2024-02-01

76
papers

2,285
citations

516215

16
h-index

253896

43
g-index

86
all docs

86
docs citations

86
times ranked

3180
citing authors

#	ARTICLE	IF	CITATIONS
1	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β^2 -Thalassemia. <i>New England Journal of Medicine</i> , 2021, 384, 252-260.	13.9	939
2	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e185-e193.	2.2	271
3	Base editing of haematopoietic stem cells rescues sickle cell disease in mice. <i>Nature</i> , 2021, 595, 295-302.	13.7	175
4	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. <i>Blood Advances</i> , 2019, 3, 3379-3392.	2.5	121
5	Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. <i>Blood</i> , 2018, 132, 2506-2519.	0.6	120
6	Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T cell therapy. <i>British Journal of Haematology</i> , 2021, 194, 701-707.	1.2	61
7	Single-nucleotide-level mapping of DNA regulatory elements that control fetal hemoglobin expression. <i>Nature Genetics</i> , 2021, 53, 869-880.	9.4	37
8	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
9	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
10	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	0.6	34
11	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. <i>Bone Marrow Transplantation</i> , 2020, 55, 929-938.	1.3	31
12	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. <i>Haematologica</i> , 2020, 105, e497.	1.7	29
13	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	3.3	28
14	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. <i>Blood Advances</i> , 2021, 5, 2403-2411.	2.5	24
15	Ethical issues in the care of adolescent and young adult oncology patients. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27608.	0.8	22
16	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	2.5	20
17	Dyskeratosis congenita caused by a novel TERT point mutation in siblings with pancytopenia and exudative retinopathy. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2302-2304.	0.8	17
18	Genetic therapies for the first molecular disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17

#	ARTICLE	IF	CITATIONS
19	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. <i>Blood Advances</i> , 2021, 5, 2839-2851.	2.5	14
20	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
21	Comparison of total body irradiation <i></i> versus <i></i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. <i>Haematologica</i> , 2021, 106, 1839-1845.	1.7	13
22	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
23	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 34-42.	0.6	13
24	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	2.0	12
25	Hematopoietic stem cell transplantation for people with Å-thalassaemia major. <i>The Cochrane Library</i> , 2016, 11, CD008708.	1.5	11
26	Gene therapy for haemophilia. <i>The Cochrane Library</i> , 2016, 12, CD010822.	1.5	9
27	Reducedâintensity conditioningâbased hematopoietic cell transplantation for dyskeratosis congenita: Singleâcenter experience and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29177.	0.8	9
28	Bilateral cystic nephroma with pleuropulmonary blastoma. <i>BMJ Case Reports</i> , 2011, 2011, bcr0520114171-bcr0520114171.	0.2	8
29	Splenectomy for people with thalassaemia major or intermedia. <i>The Cochrane Library</i> , 2016, , CD010517.	1.5	8
30	Should Poor Social Support Be an Exclusion Criterion in Bone Marrow Transplantation?. <i>American Journal of Bioethics</i> , 2019, 19, 39-41.	0.5	8
31	Adenosine Base Editing of Î³-Globin Promoters Induces Fetal Hemoglobin and Inhibit Erythroid Sickling. <i>Blood</i> , 2020, 136, 21-22.	0.6	8
32	Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. <i>Bone Marrow Transplantation</i> , 2021, 56, 1866-1875.	1.3	7
33	Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 696.e1-696.e7.	0.6	7
34	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
35	Sub acute sclerosing pan encephalitis despite adequate vaccination. <i>Australasian Medical Journal</i> , 2012, 5, 359-361.	0.1	6
36	Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. <i>Journal of Pediatrics</i> , 2015, 166, 204.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Mitigating Challenges in Dual-Role Consent: Honoring Patient Preferences to Discuss Research Participation With Someone They Know. <i>American Journal of Bioethics</i> , 2019, 19, 30-32.	0.5	5
38	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-797.	1.3	5
39	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
40	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	0.6	5
41	Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 107.e1-107.e8.	0.6	5
42	Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. <i>Blood Advances</i> , 2022, , .	2.5	5
43	Hematopoietic stem cell transplantation for people with β -thalassaemia major. , 2011, , CD008708.		4
44	Hematopoietic stem cell transplantation for people with β -thalassaemia major. , 2014, , CD008708.		4
45	Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk. <i>American Journal of Bioethics</i> , 2020, 20, 106-108.	0.5	4
46	Clinical experience of coronavirus disease 2019 in hematopoietic cell transplant and chimeric antigen receptor T-cell recipients. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 394-400.	1.2	4
47	Outcomes of pediatric patients with therapy-related myeloid neoplasms. <i>Bone Marrow Transplantation</i> , 2021, 56, 2997-3007.	1.3	4
48	Evidence- Based Medicine for Medical Students. <i>Australasian Medical Journal</i> , 2008, , 190-193.	0.1	4
49	Mortality and morbidity patterns among HIV patients with prognostic markers in a tertiary care hospital in southern India. <i>Australasian Medical Journal</i> , 2011, 4, 273-276.	0.1	3
50	Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e479-e485.	0.3	3
51	Germline Gene Editing for Sickle Cell Disease. <i>American Journal of Bioethics</i> , 2020, 20, 46-49.	0.5	3
52	Haploidentical CD45RA-Negative Donor Lymphocyte Infusions Are Feasible, Safe and Associated with Clinical Benefit. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S268.	2.0	3
53	Targeting plasma cells with daratumumab aids in the treatment of post-transplant autoimmune-like hepatitis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29290.	0.8	3
54	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. <i>Blood</i> , 2018, 132, 3641-3641.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
56	Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. <i>Cytotherapy</i> , 2022, 24, 884-891.	0.3	3
57	Designing a Research Mentorship Program (RMP) to enhance research productivity at Ebne-Sina psychiatric hospital. <i>Australasian Medical Journal</i> , 2008, , 180-182.	0.1	2
58	Cochrane: spreading the message of research to students and juniors. , 2011, , ED000026.		2
59	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> . 2022, 57, 1150-1163.	1.3	2
60	Writing for publication “ raising standards at the AMJ. <i>Australasian Medical Journal</i> , 2011, 4, 225-228.	0.1	1
61	Vasculitis Causing Complete Occlusion of Aorta. <i>Journal of Pediatrics</i> , 2015, 167, 206-206.e2.	0.9	1
62	Case 2: Prolonged Hypoglycemia in an Adolescent without Diabetes. <i>Pediatrics in Review</i> , 2016, 37, 304-306.	0.2	1
63	Hypocalcemic Tetany After Transfusion of a Small Amount of Blood Product. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 629-632.	0.3	1
64	CRISPR-Cas9 Genome Editing of $\hat{\beta}^3$ -Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of $\hat{\beta}^2$ -Hemoglobinopathies. <i>Blood</i> , 2019, 134, 2066-2066.	0.6	1
65	Administration of a Tryptophan Metabolite, Indole-3-Carboxaldehyde, Reduces Graft Versus Host Disease Morbidity and Mortality and Enhances Gastrointestinal Barrier Function in a Murine Model of Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 2014, 124, 2420-2420.	0.6	1
66	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 262.e1-262.e10.	0.6	1
67	Late pulmonary complications related to cancer treatment in children. <i>Pediatric Radiology</i> , 2022, 52, 2029-2037.	1.1	1
68	Early pulmonary complications related to cancer treatment in children. <i>Pediatric Radiology</i> , 2022, 52, 2017-2028.	1.1	1
69	Migration and Health. <i>Australasian Medical Journal</i> , 2008, , 3-8.	0.1	0
70	Allogeneic Hematopoietic Cell Transplantation for Acute Megakaryoblastic Leukemia: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S299-S300.	2.0	0
71	Aeromedical Transport of Critically Ill Infants Less Than 3 Months of Age. <i>Global Pediatric Health</i> , 2017, 4, 2333794X1773974.	0.3	0
72	An Extravagant Gift From a Grateful Patient. <i>Pediatrics</i> , 2018, 141, .	1.0	0

#	ARTICLE	IF	CITATIONS
73	Reduced Intensity Vs Myeloablative Conditioning Regimen for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S14-S15.	2.0	0
74	Second Allogeneic Hematopoietic Cell Transplant Is a Successful Salvage Modality for Pediatric Patients Who Relapse after First Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S85-S86.	2.0	0
75	Sequential Infusion of Tcr ^{hi} ± ^{hi} 2- and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies. <i>Blood</i> , 2018, 132, 4574-4574.	0.6	0
76	Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor. <i>Blood</i> , 2019, 134, 1964-1964.	0.6	0